Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Ensimmäisen linjan karboplatiini ja paklitakseli yhdistelmänä pembrolitsumabin kanssa, jota seuraa ylläpitohoito pembrolitsumabi Nesuparibin kanssa tai ilman, potilailla, joilla on äskettäin diagnosoitu pitkälle edennyt tai toistuva MMR-taitoinen (pMMR) kohdun limakalvosyöpä (PENELOPE)

perjantai 13. marraskuuta 2026 päivittänyt: JUNGYUN LEE, Yonsei University

Vaiheen 2 tutkimus ensilinjan karboplatiinista ja paklitakselista yhdistelmänä pembrolitsumabin kanssa, jota seuraa ylläpitohoito pembrolitsumabilla Nesuparibin kanssa tai ilman sitä potilailla, joilla on äskettäin diagnosoitu pitkälle edennyt tai uusiutuva kohdun limakalvon syöpä (pMMR)

The goal of this study is listed below.

Part A (Safety Run-in Phase) : To determine feasibility of pembrolizumab and nesuparib combination as maintenance therapy in patients with MMR-proficient advanced and recurrent endometrial cancer. Feasibility is defined as a dose-limiting toxicity (DLT) rate less than or equal to 33%.

Part B (Randomization Phase)

: To evaluate the efficacy of pembrolizumab and nesuparib combination/ pembrolizumab monotherapy as maintenance therapy in patients with MMR-proficient advanced stage and recurrent endometrial cancer. Efficacy will be assessed by investigator assessed progression free survival (PFS) as assessed by RECIST 1.1.

Tutkimuksen yleiskatsaus

Yksityiskohtainen kuvaus

Part A(Safety Run-in Phase) - Pembrolizumab+ paclitaxel+ carboplatin followed by pembrolizumab combination with nesuparib

Part B(Randomization Phase)

- Pembrolizumab+ p aclitaxel+ Carboplatin followed by Pembrolizumab combination with Nesuparib vs Pembrolizumab+ Paclitaxel+ Carboplatin followed by Pembrolizumab monotherapy

Opintotyyppi

Interventio

Ilmoittautuminen (Arvioitu)

92

Vaihe

  • Vaihe 2

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskeluyhteys

  • Nimi: JUNGYUN LEE, Ph.D
  • Puhelinnumero: +82-2-2228-0430
  • Sähköposti: irb@yuhs.ac

Opiskelupaikat

      • Seoul, Etelä -Korea
        • Rekrytointi
        • Samsung Medical Center
        • Ottaa yhteyttä:
      • Seoul, Etelä -Korea
        • Rekrytointi
        • Seoul National University Hospital
        • Ottaa yhteyttä:
          • Se Ik Kim
          • Puhelinnumero: +82-2-2072-0694
          • Sähköposti: irb@snuh.org
        • Päätutkija:
          • Se Ik Kim, Ph.D
      • Seoul, Etelä -Korea
        • Rekrytointi
        • Korea University Guro Hospital
        • Ottaa yhteyttä:
      • Seoul, Etelä -Korea, 03722
        • Rekrytointi
        • Severance hospital
        • Ottaa yhteyttä:
          • Jung-Yun Lee
          • Puhelinnumero: +82-2-2228-0430
          • Sähköposti: irb@yuhs.ac
        • Päätutkija:
          • Jung-Yun Lee, Ph.D
      • Seoul, Etelä -Korea
        • Rekrytointi
        • Seoul Asan Medical Center
        • Ottaa yhteyttä:
        • Päätutkija:
          • Jeong-Yeol Park, Ph.D
    • Gyeonggi-do
      • Seongnam-si, Gyeonggi-do, Etelä -Korea, 13620
        • Rekrytointi
        • Seoul National University Bundang Hospital
        • Ottaa yhteyttä:
    • Kyeonggi-do
      • Goyang-si, Kyeonggi-do, Etelä -Korea, 10408
        • Rekrytointi
        • National Cancer Center
        • Ottaa yhteyttä:
          • Myoung Cheol Lim
          • Puhelinnumero: +82-31-920-0432
          • Sähköposti: irb@ncc.re.kr
        • Päätutkija:
          • Myoung Cheol Lim, Ph.D
    • Seoul
      • Seoul, Seoul, Etelä -Korea, 06591
        • Rekrytointi
        • The Catholic University of Korea, Seoul St. Mary's Hospital
        • Ottaa yhteyttä:

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

19 vuotta ja vanhemmat (Aikuinen, Vanhempi Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Ei

Sukupuolet, jotka voivat opiskella

Nainen

Kuvaus

[Inclusion Criteria]

  1. Patient must be female ≥ 19 years of age

  2. Histologic confirmation of the original primary tumor is required. Patients with the following histologic types are eligible: Endometrioid adenocarcinoma, serous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, carcinosarcoma, adenocarcinoma not otherwise specified (N.O.S.).

  3. Measurable stage III, measurable stage IVA, stage IVB-IVC (with or without measurable disease) or recurrent (with or without measurable disease) endometrial cancer(based on the 2023 FIGO classification).

  4. MMR proficient confirmed by institutional (local) MMR IHC testing using a 4-marker panel(MSH2, MSH6, PMS2, MLH1).

  5. Patient must provide the institutional (local) P53 IHC result.

  6. Prior Therapy;

    • Naïve to first line systemic anti-cancer treatment. For patients with recurrent disease only, prior systemic anti-cancer treatment is allowed only if provided adjuvant chemotherapy was completed ≥ 12 months prior to randomization.

      a.Note : For Part A(Safety lead in phase), patient who used Paclitaxel, Carboplatin and Pembrolizumab for first line systemic therapy can participate if they meet all of the following conditions. Patient must have had 6 cycles of chemotherapy; patient must have physician assessed stable disease (SD), partial response (PR), or complete response (CR) after 6 cycles of therapy and patient must be enrolled within 9 weeks of their last dose of chemotherapy (last dose is the day of the last infusion)

    • Patients may have received prior radiation therapy for treatment of endometrial cancer. Prior radiation therapy may have included pelvic radiation therapy, extended field pelvic/para-aortic radiation therapy, and/or intravaginal brachytherapy. All radiation therapy must be completed at least 4 weeks prior to randomization.

    • Patients may have received prior hormonal therapy for treatment of endometrial cancer. All hormonal therapy must be discontinued at least three weeks prior to randomization.

  7. Archival tumor tissue available or a fresh biopsy must be obtained prior to randomization.

  8. Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2

  9. Have adequate organ function as defined in the following table (Table 2). Specimens must be collected within 7days prior to the start of study intervention.

1) Hematological Function:

  • Absolute neutrophil count (ANC) ≥1,500/µL without growth factor support within 2 weeks of screening.

  • Platelet count ≥100,000/µL without transfusion within 2 weeks of screening.

  • Hemoglobin ≥10.0 g/dL without transfusion within 2 weeks of screening. 2) Renal Function:

  • Serum creatinine ≤1.5 × upper limit of normal (ULN), OR measured or calculated creatinine clearance (CrCl) ≥30 mL/min for participants with creatinine levels >1.5 × institutional ULN. Glomerular filtration rate (GFR) may be used instead of creatinine or CrCl. Creatinine clearance should be calculated according to institutional standards.

    3) Hepatic Function:

  • Total bilirubin ≤1.5 × ULN, OR direct bilirubin ≤ULN for participants with total bilirubin levels >1.5 × ULN.

  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3 × ULN, or ≤5 × ULN for participants with liver metastases.

    4) Coagulation Function:

  • International normalized ratio (INR) or prothrombin time (PT), and activated partial thromboplastin time (aPTT) ≤1.5 × ULN, unless the participant is receiving anticoagulant therapy, provided that PT or aPTT is within the therapeutic range of the intended anticoagulant use.

    5) Thyroid Function:

  • Thyroid-stimulating hormone (TSH) within normal limits (WNL). TSH below the ULN is allowed in euthyroid patients receiving thyroid replacement therapy. Participants with abnormal TSH are eligible if free T4 is normal and the participant is clinically euthyroid.

    10.Patient has voluntarily agreed to participate by giving written informed consent/assent for the trial.

    11.Women of childbearing potential (WOCBP) must agree to use adequate contraception (hormonal method or abstinence, contraceptive procedure (IUD, Mirena, etc.)) from up to 14 days prior to randomization (for oral contraceptives), during treatment, and for 6 months after the last dose of Paclitaxel + Carboplatin, for 4 months after the last dose of Pembrolizumab, for 3 months after the last dose of Nesuparib, whichever occurs last.

    12.Should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately. Patients will be considered of nonreproductive potential if they are either:

  • Postmenopausal (defined as at least 12 months with no menses without an alternative medical cause; in women <45 years of age, a high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy. In the absence of 12 months of amenorrhea, a single FSH measurement is insufficient); OR

  • Have a hysterectomy and/or bilateral oophorectomy, bilateral salpingectomy or bilateral tubal ligation/occlusion, at least 6 weeks prior to randomization; OR Have a congenital or acquired condition that prevents childbearing.

[Exclusion Criteria]

Participants are excluded from the study if any of the following criteria apply:

  1. Patient has undergone prior treatment with a known PARP inhibitor.

  2. Patient has a known hypersensitivity to nesuparib, pembrolizumab or combination cytotoxic chemotherapy components or excipients.

  3. MMR deficiency confirmed by institutional MMR IHC testing.

  4. Patient has received prior treatment with immune-oncology agents as part of anti-cancer therapies.

  5. Patients who are currently participating and receiving cancer-directed study therapy or have participated in a study of an investigational agent and received cancer-directed study therapy within 4 weeks prior to randomization.

  6. Patient has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Patients with treated brain metastases may be eligible if follow-up brain imaging after CNS directed therapy shows no evidence of progression, and they have been off steroids for at least 4 weeks prior to randomization and remain clinically stable.

  7. Patient has a known additional malignancy that progressed or required active treatment within the last 2 years. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy, or in situ cervical cancer.

  8. Patient has received a live vaccine or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed.

  9. Patient has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to randomization.

    • Patients who have received steroids as CT scan contrast premedication may be enrolled.
    • The use of inhaled or topical corticosteroids is allowed.
    • The use of mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed.
    • The use of physiologic doses of corticosteroids may be approved after consultation with the study chair.
  10. Patients who have a history of (non-infectious) pneumonitis that required steroids, or current pneumonitis.

  11. Patient with uncontrolled intercurrent illness including, but not limited to: ongoing or active infection (except for uncomplicated urinary tract infection), interstitial lung disease or active, noninfectious pneumonitis, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

  12. Patient has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)

  13. History of Hepatitis B (defined as HBsAg reactive) or known active Hepatitis C virus (defined as detectable HCV RNA [qualitative]) infection. Note: Testing for Hepatitis B or C is not required unless mandated by local health authority.

  14. Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication.

  15. Patient has known history or current diagnosis of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).

  16. Patients with systemic autoimmune disease such as Systemic Lupus Erythematosus.

  17. Has not adequately recovered from major surgery or has ongoing surgical complications.

  18. Has a history or current evidence of any condition, therapy, or laboratory abnormality or other circumstance that might confound the results of the study, interfere with the participant's participation for the full duration of the study, such that it is not in the best interest of the participant to participate, in the opinion of the treating investigator.

  19. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.

  20. Is pregnant or breastfeeding or expecting to be pregnant or conceive children within the projected duration of the study, starting with the screening visit through 6 months after the last dose of Paclitaxel + Carboplatin, 4 months after the last dose of Pembrolizumab, 3 months after the last dose of Nesuparib, whichever occurs last.

  21. Has had an allogenic tissue/solid organ transplant.

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Hoito
  • Jako: Satunnaistettu
  • Inventiomalli: Rinnakkaistehtävä
  • Naamiointi: Ei mitään (avoin tarra)

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Kokeellinen: Part B - Pembrolizumab monotherapy

Chemotherapy Treatment Pembrolizumab 200 mg IV Day 1 + Paclitaxel 175mg/m2 IV over 3 hours Day 1 + Carboplatin AUC 5 IV Day 1 x 6 cycles (one cycle = 3 weeks

Maintenance Treatment Pembrolizumab 400 mg IV Day 1 x up to 14 cycles (o ne cycle = 6 weeks )

Maximum number of Pembrolizumab cycles (Chemotherapy Treatment + maintenance Treatment ) = 20

Pembrolizumab 400mg, IV, Q6W

Kokeellinen: Part B - Pembrolizumab and nesuparib combination therapy

Combination therapy Chemotherapy Treatment Pembrolizumab 200 mg IV Day 1 + Paclitaxel 175mg/m2 IV over 3 hours Day + Carboplatin AUC 5 IV Day 1 x 6 cycles (one cycle = 3 weeks)

Maintenance Treatment Pembrolizumab 400 mg IV Day 1 + Nesuparib 150mg or 100mg QD PO x up to 14 cycles (o ne cycle = 6 weeks )

Maximum number of Pembrolizumab cycles (Chemotherapy Treatment + maintenance Treatment ) = 20

Pembrolizumab 400mg, IV, Q6W

Nesuparib 150mg or 100mg, QD, PO

Kokeellinen: Part A - Safety Run-in Phase

Chemotherapy Treatment:

Pembrolizumab 200 mg IV Day 1 + Paclitaxel 175mg/m2 IV over 3 hours Day 1 + Carboplatin AUC 5 IV Day 1 x 6 cycles (one cycle = 3 weeks)

Maintenance Treatment:

Pembrolizumab 400 mg IV Day 1 + Nesuparib 150mg or 100mg QD PO x up to 14 cycles (one cycle = 6 weeks)

Maximum number of Pembrolizumab cycles (Chemotherapy Treatment + Maintenance Treatment) = 20

Pembrolizumab 400mg, IV, Q6W

Nesuparib 150mg or 100mg, QD, PO

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Dose-limiting toxicities
Aikaikkuna: Assessed during 21days from day 1 of first combination maintenance treatment cycle (i.e., 21 days of Cycle 8 from day 1)

In Part A, To evaluate dose-limiting toxicities(DLTs) of combination maintenance treatment with pembrolizumab and nesuparib during the 21 days from first nesuparib and pembrolizumab administration, and to establish a recommended Phase 2 dose(RP2D) and dosing schedule.

Assessed during 21days from day 1 of first combination maintenance treatment cycle (i.e., 21 days of Cycle 8 from day 1)
Overall distribution of progression-free survival
Aikaikkuna: Approximately 11.01 months

The time from randomization to the time when Progressive disease(PD) is first confirmed after administration of the first investigational drug (Pembrolizumab) or until death without disease progression.

Approximately 11.01 months

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
3, 6, 9 12-month Progression-free rate(PFS rate)
Aikaikkuna: 3month, 6month, 9month, 12month after the study enrollment

the proportion of patients who are alive and without disease progression after administering the investigational product

3month, 6month, 9month, 12month after the study enrollment
Median Progression-free time(Median PFS time)
Aikaikkuna: All 36 subjects in each groups are enrolled and the 18-month follow-up period ends

the proportion of patients who are alive and without disease progression after administering the investigational product

All 36 subjects in each groups are enrolled and the 18-month follow-up period ends
Overall response rate(ORR)
Aikaikkuna: All 36 subjects in each groups are enrolled and the 18-month follow-up period ends

the proportion of patients achieving complete remission(CR) or partial response(PR) as assessed by the Investigator per RECIST(v1.1) in patients who enter the study with measurable disease.

All 36 subjects in each groups are enrolled and the 18-month follow-up period ends
Duration control rate(DCR)
Aikaikkuna: All 36 subjects in each groups are enrolled and the 18-month follow-up period ends

the proportion of subjects who have achieved a best overall response of complete remission(CR), partial response(PR), or stable disesae(SD) per RECIST v.1.1 based on Investigator assessment.

All 36 subjects in each groups are enrolled and the 18-month follow-up period ends
Duration of response(DOR)
Aikaikkuna: All 36 subjects in each groups are enrolled and the 18-month follow-up period ends

DOR applies only to subjects whose BOR was CR or PR in patients who enter the study with measurable disease according to RECIST v.1.1 using the Investigator's tumor assessment. The start date is the date of first documented response (CR or PR), and the end date is the date defined as first documented PD or death due to any cause. If a subject had not had an event, duration will be censored at the date of last adequate tumor assessment.

All 36 subjects in each groups are enrolled and the 18-month follow-up period ends
Overall survival(OS)
Aikaikkuna: All 36 subjects in each groups are enrolled and the 18-month follow-up period ends

the time from the first date of investigational product administration to the date of death for any reason.

All 36 subjects in each groups are enrolled and the 18-month follow-up period ends
Progression free survival 2(PFS2)
Aikaikkuna: All 36 subjects in each groups are enrolled and the 18-month follow-up period ends

the time from the first date of administration of the investigational product to the earlier of disease progression or death in the subsequent anticancer therapy.

All 36 subjects in each groups are enrolled and the 18-month follow-up period ends

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Julkaisuja ja hyödyllisiä linkkejä

Tutkimusta koskevien tietojen syöttämisestä vastaava henkilö toimittaa nämä julkaisut vapaaehtoisesti. Nämä voivat koskea mitä tahansa tutkimukseen liittyvää.

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Torstai 12. syyskuuta 2024

Ensisijainen valmistuminen (Arvioitu)

Maanantai 27. joulukuuta 2027

Opintojen valmistuminen (Arvioitu)

Maanantai 27. joulukuuta 2027

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Sunnuntai 23. kesäkuuta 2024

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Tiistai 9. heinäkuuta 2024

Ensimmäinen Lähetetty (Todellinen)

Tiistai 16. heinäkuuta 2024

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Maanantai 16. marraskuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Perjantai 13. marraskuuta 2026

Viimeksi vahvistettu

Sunnuntai 1. marraskuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa